November 6, 2009 1:02 PM
- Text
Pfizer Aiming for 30,900 Layoffs Through 2012
(MoneyWatch) Pfizer (PFE) has laid off 26,300 employees since 2005, and hopes eventually to lay off a total of 30,900 through 2012, according to its 10-Q filing with the SEC.
The company had several rounds of layoffs before its acquisition of Wyeth in an attempt to get $6 billion in annual savings out of its business model. The company has said it wants to ax about 19,500 jobs to make the Wyeth merger work. The new company will have about 130,000 workers. The layoffs are ongoing, Pfizer said:
And finally: Although Pfizer's troubles with the states and the feds over Bextra are all wrapped up, shareholders have just gotten started. A number of shareholder derivative actions have been filed. Pfizer said:
The company had several rounds of layoffs before its acquisition of Wyeth in an attempt to get $6 billion in annual savings out of its business model. The company has said it wants to ax about 19,500 jobs to make the Wyeth merger work. The new company will have about 130,000 workers. The layoffs are ongoing, Pfizer said:
In the third quarter of 2009, we reduced our workforce by approximately 1,100 employees and, in the first nine months of 2009, we reduced our workforce by approximately 6,500 employees.Pfizer gives two sets of costs related to all those layoffs. On page 9 the company says:
During the first nine months of 2009 we expensed $200 million for Employee termination costs ...That would mean it costs about $30,769 per employee in severance payments and benefits. But on page 33, in a discussion of workforce reduction, Pfizer adds:
During the third quarter of 2009, we incurred costs related to this cost-reduction initiative of $141 million and, in the first nine months of 2009, we incurred costs related to this cost-reduction initiative of $802 million.That works out at about $123,385 per employee -- a similar sum associated with Merck's layoff program.
And finally: Although Pfizer's troubles with the states and the feds over Bextra are all wrapped up, shareholders have just gotten started. A number of shareholder derivative actions have been filed. Pfizer said:
These actions allege that the individual defendants breached fiduciary duties by causing or allowing Pfizer to engage in off-label promotion of certain drugs, including Bextra.
Latest Now in MoneyWatch
- States, Feds to announce new mortgage settlement
- Management changes at Ford
- Unemployment aid applications near a 4-year low
- PepsiCo's net rises; plans to cut 8,700 jobs
- Smartr: A brilliant contacts app for smartphones
- What happens if your insurance company fails?
- Student loan debt: the next financial disaster?
- Investing: Four words that can rob you blind
- How to get the fastest tax refund
- 10 employee types that drive managers crazy
- How leaders know it's time to quit
- Greece fails to agree terms with EU creditors
- 5 banks in $26B settlement with feds over abuses
- Gas prices continue to creep up
- Joe Coffee | Secrets of Successful Startups
- Small business mistake: coasting on past success
- Groupon's revenue, losses grow quarter to quarter
Latest CBS News Headlines
on Facebook
on CBS News
- Ariz. tribe votes to take over Skywalk management
- Wash. moves step closer to legalizing gay marriage
- Greek debt crisis eases, but drama is not over
- Greek debt crisis eases, but drama is not over
on Facebook
- Calif. surfer runs fastest-growing camera company
- Mo. teen gets life in prison for murder of 9-year-old girl
- "Person to Person": Bon Jovi behind the scenes
- Zsa Zsa at 95: Husband releases birthday photos
on CBS News






